# A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia

> **NCT07498465** · PHASE1 · WITHDRAWN · sponsor: **Children's Oncology Group**

## Conditions studied

- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Childhood Acute Lymphoblastic Leukemia
- Childhood Acute Myeloid Leukemia
- Childhood Mixed Phenotype Acute Leukemia
- Mixed Phenotype Acute Leukemia

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **DRUG:** Cytarabine
- **PROCEDURE:** Echocardiography Test
- **DRUG:** Methotrexate
- **PROCEDURE:** Radiologic Examination
- **DRUG:** Revumenib
- **DRUG:** Therapeutic Hydrocortisone

## Key facts

- **NCT ID:** NCT07498465
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2026-09-10
- **Primary completion:** 2028-11-12
- **Final completion:** 2028-11-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Other - Protocol moved to Withdrawn
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07498465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07498465, "A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07498465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*